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Abstract
Background: There is a strong association between bipolar disorder (BD) and substance use disorder (SUD). The
clinical and functional correlates of SUD in BD are still unclear and little is known about the role of excessive
substance use that does not meet SUD criteria. Thus, the aims of the current study were to investigate lifetime
rates of illicit substance use in BD relative to the normal population and if there are differences in clinical and
functional features between BD patients with and without excessive substance use.
Methods: 125 consecutively recruited BD in- and outpatients from the Oslo University Hospitals and 327 persons
randomly drawn from the population in Oslo, Norway participated. Clinical and functional variables were assessed.
Excessive substance use was defined as DSM-IV SUD and/or excessive use according to predefined criteria.
Results: The rate of lifetime illicit substance use was significantly higher among patients compared to the
reference population (OR = 3.03, CI = 1.9-4.8, p < .001). Patients with excessive substance use (45% of total) had
poorer educational level, occupational status, GAF-scores and medication compliance, with a trend towards higher
suicidality rates, compared to patients without. There were no significant group differences in current symptom
levels or disease course between groups.
Conclusion: The percentage of patients with BD that had tried illicit substances was significantly higher than in
the normal population. BD patients with excessive substance use clearly had impaired functioning, but not a worse
course of illness compared to patients without excessive substance use. An assessment of substance use beyond
SUD criteria in BD is clinically relevant.
Background
Comorbid bipolar disorder (BD) and substance use dis-
order (SUD) have been found to be highly prevalent in
both epidemiological and clinical studies, with rates of
SUD in subjects with BD ranging from 35-60% [1-6].
The high prevalence is found across different age groups
and also in first episode BD samples [7,8].
So far, most studies in BD have investigated only sub-
stance use fulfilling SUD criteria. Investigating a broader
range of substance use in BD could be relevant because
people with severe mental disorders are more likely to
experience negative consequences from using relatively
small amounts of psychoactive substances [9]. Moderate
alcohol consumption in BD is associated with more
severe manic symptoms compared to abstinence, and to
poorer social and familial adjustment and increased
health-care use [10]. To the best of our knowledge, only
one study assessed substance use in BD more globally,
reporting that 46% had SUDs and 8% had SUD-sub-
threshold substance use. In addition, the authors indi-
cated that another substantial proportion used illicit
substances occasionally [11].
Clarifying whether there is an increased use of sub-
stances in BD may increase our understanding of the
psychopathology underlying the increased risk of abuse
or dependence. Although most studies show a large pre-
valence of BD and SUD comorbidity, the rates vary
* Correspondence: t.v.lagerberg@medisin.uio.no
1Section for Psychosis Research, Oslo University Hospital, Bygg 49, Kirkevn.
166, N-0407 Oslo, Norway
Lagerberg et al. BMC Psychiatry 2010, 10:9
http://www.biomedcentral.com/1471-244X/10/9
© 2010 Lagerberg et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
widely. This variation could be mirroring differences in
substance use in the general population where the BD
sample is recruited. In a smaller sample from an earlier
part of our ongoing study, we showed elevated rates of
lifetime use of illicit substances among patients with
psychotic disorders (including BD) compared to the
general population [12], and differences in patterns of
substance use between schizophrenia and BD [13]. Due
to the small number of patients with BD included in
our earlier report, a separate comparison of BD patients
with the general population sample was not implemen-
table. Thus, there is a need for studies comparing BD
subjects with reference populations on substance use
and they should be done with samples from the same
geographical area within the same time period.
In the current literature, BD with comorbid SUD is
consistently referred to as associated with a poorer dis-
ease course and with reduced functioning compared to
BD without SUD. The findings regarding the effects of
SUD on BD are however divergent. To explore this
more thoroughly we did a search in PubMed (terms
bipolar disorder, substance abuse and outcome), and in
addition tracked all cited references in key publications
(Additional file 1). The main finding from this search
was that the only consistently reported findings were
delayed recovery and lower remission rates [14-22] as
well as faster relapses [14,23-25] in groups of BD
patients with SUD (both lifetime/current substance -
and/or alcohol use disorders) compared to BD without
SUD. Furthermore, there appears to be extensive evi-
dence for elevated suicidality rates in BD with SUD
compared to BD without [18,20,26-37], although several
studies also report no significant differences [19,38-42].
Medication compliance rates are also relatively consis-
tently reported to be lower in BD with SUD compared
to BD without [18,19,29,43-46] although a few studies
report lack of differences [38,42]. Another consistent
finding is that the prevalence of psychotic symptoms
does not appear to be elevated among BD patients with
SUD compared to patients without [18,19,28,38,47,48],
and there is neither a tendency towards increased num-
bers of affective episodes [19,27,31,48,49].
The findings are more divergent regarding rapid cycling;
as some studies did [38,40,50-52] and some did not
[19,29,53] find this to be more prevalent in the SUD
patients. The same inconsistency is found for the preva-
lence of mixed episodes, some studies found this phenom-
enon to be more common [14,18,39,50,54] while others
did not [17,47,55] in the SUD patients. There are
also inconsistencies regarding age of onset for BD;
here some report earlier onset for patients with
SUD [26,29-31,50,51,56,57] while others do not find any
differences compared to BD patients without SUD
[18,19,38,47,55,58]. Studies also diverge as to whether
affective symptoms are of increased severity in BD patients
with SUD compared to BD patients without
[18,21,26,39,42,47,49,50,59,60]. Furthermore, the number
of hospitalizations or days in hospital is found to be eleva-
ted in BD patients with SUD in some studies
[29,31,50,55,61-64] as opposed to in others
[18,26-28,38,48,56,65].
Findings concerning other functional variables such as
decreased global functioning [19,26,38,39,47,48,56,60,66],
social functioning [20,21,27,29,38,58,60,67], educational
level [19,20,26,31,38,50,56,60], and quality of life
[20,21,26,58,60,61] in BD with SUD also diverge. Finally,
some studies find lower employment status in BD with
SUD compared to BD without [21,24,29,67] while others
do not [28,43,50,56], and two studies even find better
employment rates in BD with SUD [19,61]. The current
evidence therefore suggests that BD with comorbid SUD
is clearly associated with worsening of some clinical and
functional characteristics: Length of affective episodes
and relapse rates, risks of suicidality and compliance to
medication. However, substance abuse does not appear
to be as consistently associated with a more severe
course and outcome as frequently indicated in the
literature.
In the present study, we aim at investigating differ-
ences in relevant outcome variables in a sample of BD
patients with and without substance use. The present
paper is based on a cross-sectional study of consecu-
tively referred patients with BD from a catchment-area
based psychiatric service, and a population survey of the
use of illicit substances in the same area within the
same time period. Our aims were to answer the follow-
ing questions:
1) Is the rate of lifetime use of illicit substances higher
in the patient sample than in the reference population?
2) Do patients with and without excessive substance
use, defined as SUD and/or excessive use, differ on clini-
cal and functional characteristics, in terms of disease
course variables, current symptom levels and
functioning?
Methods
Participants
125 patients with DSM-IV bipolar disorder (BD I n = 71
and BD II n = 54), participated in the study. The sample
is part of an ongoing study of schizophrenia and bipolar
disorder (the Thematically Organized Psychosis
Research - TOP study). The BD patients were consecu-
tively recruited between 2003 and 2007 from the psy-
chiatric units (in- and outpatient) of the three major
hospitals in Oslo. The exclusion criteria for all partici-
pants were: history of moderate/severe head injury, neu-
rological disorder, mental retardation, age outside the
range of 18-65 years, and not speaking a Scandinavian
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language. All participants gave informed consent, and
the project was approved by the Regional Committee
for Medical Research Ethics and the Norwegian Data
Inspectorate.
A sample from the general population was used as a
reference group for rates of lifetime use of illicit sub-
stances, collected by the Norwegian Institute for Alcohol
and Drug Research (SIRUS). SIRUS regularly conducts
surveys of the Norwegian population’s consumption of
illicit substances by personal interviews via standardized
questionnaires. Subjects are randomly selected according
to a detailed selection protocol and weighted to age, gen-
der and address [68]. For the purpose of this study, we
used a reference group of 327 subjects from 2004 SIRUS
data for Oslo, with participants aged 18-65. There was no
age difference between the patient group and the refer-
ence group (35.6, SD 11.7 vs. 36.0, SD 12.0), but the pro-
portion of women was significantly greater in the patient
sample (64.8% vs. 51.4%, Χ2 = 6.59, df = 1, p = 0.010).
Clinical assessment
Clinical assessment was carried out by trained clinical
psychologists and psychiatrists. Diagnoses were estab-
lished using the Structured Clinical Interview for DSM-
IV, modules A-E [69]. General non-psychotic symptoms
were assessed by the Positive and Negative Syndrome
Scale (PANSS) [70], depressive symptoms with the IDS-
C [71], (hypo)manic symptoms with the Young Mania
Rating Scale (YMRS) [72] and current functioning by
the Global Assessment of Functioning Scale (GAF) [73],
split version [74]. The Medication Adherence Rating
Scale (MARS) [75] was used to measure compliance to
medication. A total of 103 patients (82.4%) completed
the MARS. Eight patients (6.4%) did not complete
because they were not using any medication at the time
of the evaluation. Among the patients not completing
the MARS, there was no significant difference in the
proportion with or without excessive substance use.
All interviewers were trained based on the training
program at UCLA (CA, USA) and participated in regu-
lar diagnostic consensus meetings. A good inter-rater
reliability was achieved with an overall kappa score of
0.77 (95% CI: 0.60-0.94). The reliability for symptom
assessments was also good, with an intraclass correlation
coefficient (1.1) of 0.71 for the PANSS general subscale,
and of 0.86 for both symptom and function GAF scores
(for details, see Ringen et al. 2007b).
Some of the variables frequently reported in the litera-
ture, like prevalence of mixed episodes and rapid
cycling, were not investigated in the present study, due
to a study design that did not focus on specific charac-
teristics of the affective episodes. Disease course was
assessed by means of SCID criteria, which lack the spe-
cificity needed for satisfactory reliability of such
phenomena.
Substance use assessments and excessive substance use
definitions
Patients were asked for age at first experience with drink-
ing alcohol and using non-alcoholic drugs (including non-
prescribed anxiolytic and hypnotic medicines). Lifetime
use of all substances through age intervals (age 12-15,
16-20, 21-27, 28-44, 45-60, 60+) was registered separately
in categories of daily, weekly, monthly or occasional/no
use within each interval, based on the possibility of differ-
ent use patterns and of differences in the pathophysiologi-
cal influence of substances across different age periods.
Predominantly daily use of alcohol and predominantly
weekly use of a non-alcoholic substance throughout an age
interval across a minimum of 4 years were considered
excessive, and substance use according to these definitions
is subsequently termed excessive use. Structured interviews
about substance use during the past 6 months were per-
formed. Alcohol use was assessed by number of units and
non-alcoholic substance use by number of incidents. Dif-
ferent non-alcoholic substances were asked for specifically
and the use was quantified by totaling the number of inci-
dents recalled. Urine samples were also collected and cor-
responded well with patients’ own reports of consumption
of non-alcoholic substances in previous weeks [13]. There
were no statistically significant differences among the
levels of substance use (number of units of alcohol or
number of incidences of use of non-alcoholic substances)
the last 6 months between patients fulfilling SUD criteria
and patients with excessive use. But these two groups
combined differed significantly from the patients with
neither SUD nor excessive substance use. Thus, for the
subsequent analyses, patients with SUD and patients with
excessive use were aggregated in an “excessive substance
use group“. Patients with none of these are subsequently
named “no use group“.
The mean age was 34.8 (SD 11.8) in the excessive sub-
stance use group and 36.2 (SD 11.2) in the no use group
(n.s.). In the excessive substance use group, 54% were
female, which was significantly different from the no use
group, where 74% were female (Χ2 = 5.608, p = 0.018).
93% were Caucasian in the excessive substance use
group, and 90% in the no use group (n.s.). Median dura-
tion of illness was 9.5 years (IQR 12) in the excessive
substance use group and 11.5 years (IQR 16.75) in the
no use group (n.s.).
Statistical procedure
All analyses were done using the Statistical Package for
the Social Sciences (SPSS) version 16.0. The limit for
significance was set to 0.05 (two-sided). Chi-square tests
and Fisher’s exact tests were used when investigating
group differences on categorical data. Group differences
in independent samples were explored with Student’s
t-tests and ANOVAs on normally distributed continu-
ous variables and Mann Whitney U-tests and Kruskal
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Wallis tests for variables with a skewed distribution. The
distribution of skewed variables is presented through
medians and interquartile ranges (IQR). Binary logistic
regression analysis was used for calculating odds ratios,
controlling for relevant variables. Correlations between
group membership, outcome measures and background
variables that might mediate their relationships were
explored through Pearson and Spearman rank correla-
tions. The presence of possible confounder variables was
explored through hierarchical multiple regression analy-
sis. The Kaplan-Meier Survival Analysis was used to
compare time in remission across the two groups.
For the analyses related to research question 2, the
levels of relevant demographic and clinical measures
were compared for the excessive substance use group
versus the no use group. Since the distribution of sex
was significantly different in the excessive substance use
group and the no use group, it was considered a poten-
tial confounder in the associations between group mem-
bership and outcome variables and possible mediating
effects were investigated.
Results
The prevalence of lifetime use of illicit substances was
65% in the patient sample and 40% in the general popu-
lation sample. When corrected for age and sex, the risk
of lifetime use of illicit substances was significantly and
three times greater in the patient sample compared to
the reference population (OR = 3.03, CI = 1.9-4.8,
p < .001).
The prevalence of SUDs and excessive substance use
are presented in Table 1.
Regarding clinical and functional outcome variables
(Table 2), we found that the no use group had significantly
more years of education than the patients with excessive
substance use (15.1, SD 2.9 versus 13.5, SD 2.6, p = 0.001).
The proportion that was employed/full time students was
significantly smaller in the excessive substance use group
(21% versus 45%, p = 0.006). We also found that the exces-
sive substance use group had significantly lower mean
GAF S and F scores than the no use group (52.9, SD 10.7
versus 59.7, SD 11.1, p = 0.001 and 50.3, SD 11.3 versus
57.2, SD 12.1, p = 0.002, respectively). Correlation analyses
revealed that number of years of education correlated with
the excessive substance use group (Pearson’s r = -0.29,
p = 0.001), and GAF S and F scores (GAF S: Pearson’s
r = 0.22, p = 0.016, GAF F: Pearson’s r = 0.21, p = 0.018).
After correction for number of years of education, age and
sex, there was still a significant association between exces-
sive substance use and lower GAF S score (group mem-
bership entered as last variable, b = -0.24, p = 0.009), and
lower GAF F score (b = -0.20, p = 0.034). Furthermore,
the excessive substance use group had a significantly
higher median MARS score, i.e. was less compliant by
self-report than the no use group (8, IQR 5 versus 7, IQR
3, p = 0.010). There was also a strong trend that the exces-
sive substance use group had more suicide attempts than
the no use group (p = 0.053).
We found no significant differences in affective and
general symptomatology as measured by the IDS-score,
YMRS-score or PANSS general score between the
patients with and without excessive substance use (Table
2). The proportion of patients in remission was not sig-
nificantly different across the two groups, nor was time
in remission. No significant differences were found
between the groups in age at onset of BD, number of ele-
vated episodes (manic/hypomanic), number of depressive
episodes, or bipolar subtype distribution (BD I vs. BD II).
No significant differences between the groups were
found in lifetime prevalence of psychotic symptoms.
Regarding the latter, a separate analysis comparing
patients that only excessively used psychoactive sub-
stances known to induce psychotic symptoms (cannabis
and centrally stimulating agents) with the no use group
revealed no significant differences (Χ2 = 0.059,
p = 0.564). No significant differences were found regard-
ing lifetime hospital admission or total number of admis-
sions. Among the ones admitted, there was a trend that
the duration of admissions was shorter in the excessive
substance use group (p = 0.056). These analyses were
repeated for only patients fulfilling SUD criteria versus
the no use group (excessive use patients excluded),
revealing no additional significant differences between
the two groups. To investigate whether alcoholic and
non-alcoholic substances influenced outcome in different
directions, the alcoholic and non-alcoholic excessive sub-
stance use groups were compared with the no use group
separately. This yielded no new significant associations.
Discussion
The main findings of the present study are that patients
with BD had a significant increase (OR of 3) of lifetime
Table 1 Prevalence of lifetime substance use disorders
and of excessive use in patient sample, N (%)
N = 125
SUD total 38 (30.4)
Alcohol use disorder 26 (20.8)
Cannabis use disorder 15 (12.0)
Other non-alc. substance use disorder 14 (11.0)
Excessive use total 18 (14.4)
Excessive alcohol use 7 (5.6)
Excessive cannabis use 13 (10.4)
Excessive use other non-alc. substances 2 (1.6)
SUD + excessive use 56 (44.8)
SUD and excessive substance use are here mutually exclusive categories.
Within these categories, some patients meet the criteria for two or more
substance use disorders or can excessively use two or more substances.
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use of illicit substances compared to the general popula-
tion, and that excessive substance use was associated
with poorer functioning but not with worse illness
course characteristics or current symptom levels.
To the best of our knowledge, this is the first study to
report lifetime illicit substance use in a clinical sample
of BD patients compared to the reference population.
Our data indicate that the risk is greater than in the
general population not only to develop SUDs, but also
to use such drugs at a SUD-subthreshold level. Despite
large research efforts, the mechanisms involved in the
increased substance use in BD are not known. Several
studies have found increased impulsivity and novelty
seeking in BD patients [76,77], which have also been
linked to substance use [78,79]. This could partially
explain the increased tendency to experiment with and
excessively use substances among subjects with BD [80].
The same could be true for Behavioral Approach System
(BAS) dysregulation, in which high BAS sensitivity has
been linked to both increased risk of (hypo)manic epi-
sodes [81] and substance abuse [82]. Searching for
potential protecting factors in BD subjects not develop-
ing SUD could be a worthwhile approach for future
studies.
The total alcohol use disorder rate of 21% found in
the present study was in the lower range of earlier
clinical reports on samples consisting of both BD I and
II disorders [20,30,83], and the higher SUD rates in
males compared to females is in accordance with earlier
findings [57,58]. Thus, the somewhat higher proportion
of females in our sample could explain the lower alcohol
use disorder rate. Furthermore, both drug use and alco-
hol use patterns differ between countries and cultures.
The average alcohol intake in Norway is significantly
lower than the European continent, the UK and the US
[84,85], which could also explain the lower risk of alco-
hol use disorder in the patient group in the present
study.
There were several indicators of a poorer functioning
in the excessive substance use group compared to the
no use group, including length of education and
employment rate. The hierarchical multiple regression
analyses also indicated direct associations between
excessive substance use and lower GAF scores that were
not mediated by years of education. Although earlier
studies are inconsistent, our findings of poorer function-
ing in the excessive substance use group are in line with
several studies showing greater functional impairment
associated with comorbid SUD [20,21,29,60]. The exces-
sive substance use group also had poorer compliance,
which is in accordance with earlier research [45,46]. The
trend towards shorter hospital admissions found in the
Table 2 Clinical course and functional outcome variables in the “excessive substance use” group versus the “no use”
groups
Excessive substance No use Test statistics/p-value Effect sizes
use group, N = 56 group, N = 69
IDS-C, median (IQR) 16.5 (17) 13.5 (20) U = 1640.5, p = 0.853a
YMRS, median (IQR) 2 (3) 2 (5) U = 1730.5, p = 0.393a
PANSS general, mean (SD) 26.1 (5.9) 24.6 (6.0) t = -1.384, df = 122, p = 0.169d
Age at onset of BD (years), median (IQR) 20 (9) 19 (10) U = 1894.0, p = 0.962a
Duration of illness, median (IQR) 9.5 (12) 11.5 (16.75) U = 1739.0, p = 0.407a
In remission, n (%) 19 (35) 31 (46) X2 = 1.515, p = 0.218b
Time in remission, months, median (IQR) 3 (4) 5 (7.25) X2 = 2.511, p = 0.113c
No. of elevated mood episodes, median (IQR) 3 (8.5) 2 (4) U = 1619.0, p = 0.288a
No. of depressive episodes, median (IQR) 4 (9) 3 (8) U = 1716.0, p = 0.604a
Bipolar disorder type, BD I, n (%) 30 (54) 41 (59) X2 = 0.431, p = 0.512b
Psychosis, n (%) 20 (36) 32 (48) X2 = 1.604, p = 0.205b
No. of suicide attempts, median (IQR) 0 (1) 0 (1) U = 600.0, p = 0.053a
Hospitalized (lifetime), n (%) 35 (65) 45 (67) X2 = 0.074, p = 0.786b
No. of admissions, median (IQR) 1 (2.8) 1 (3) U = 1814.0, p = 0.745a
Duration of admissions (months), median (IQR) 1.5 (4.2) 3.3 (5) U = 568.0, p = 0.056a
MARS score, median (IQR) 8 (5) 7 (3) U = 915.5, p = 0.010a Diff. in mean rank = 15.17
Years of education, mean (SD) 13.5 (2.6) 15.1 (2.9) t = 3.307, df = 123, p = 0.001d Cohen’s d = 0.596
Currently employed/full time students, n (%) 12 (21) 31 (45) X2 = 7.564, p = 0.006b Phi = -0.246
Marital status (married/living as married), n (%) 20 (36) 26 (38) X2 = 0.051, p = 0.821
GAF S, mean (SD) 52.9 (10.7) 59.7 (11.1) t = 3.458, df = 123, p = 0.001d Cohen’s d = 0.624
GAF F, mean (SD) 50.3 (11.3) 57.2 (12.1) t = 3.112, df = 123, p = 0.002d Cohen’s d = 0.561
IQR = interquartile range. aMann Whitney U-test, bChi-square test, cLog rank (Mantel Cox) test, dStudent’s t-test.
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excessive substance use group could also be interpreted
as reduced compliance, as shorter admissions may be an
expression of treatment non-compliance. Alternatively,
inpatient treatment facilities are not optimal for treating
BD patients with excessive substance use which may
lead to shorter inpatient treatment. Shorter durations of
psychiatric hospital admissions among patients with
comorbid mental illness and SUD have also been found
in earlier studies [86].
We did not find evidence that the presence of exces-
sive substance use was associated with more severe BD
specific disease characteristics. Earlier studies mainly
investigated DSM-IV SUD, which is more narrowly
defined than the present study’s excessive substance use
category. However, when we analyzed the narrowly
defined SUD group, we did not find different results
compared to the excessive substance use group. Further-
more, we found that the substance use levels among
patients with excessive use were similar to patients with
SUDs. Comparing our results with studies investigating
SUD should therefore be relevant. The present lack of
association between excessive substance use and current
affective symptomatology is in line with several other
studies finding no differences across groups defined by
SUD in these variables [18,50]. It has also been hypothe-
sized that SUD may trigger BD in individuals without a
great constitutional vulnerability for the disorder
[48,87]. Thus, a lack of worsening of BD illness charac-
teristics in the presence of SUD may be explained by a
lower vulnerability. Our finding of no relationship
between excessive substance use and an earlier onset of
the BD is consistent with some studies [55] but in con-
trast to others [29], and these discrepancies are difficult
to explain. The present lack of significant differences in
remission variables was unexpected, since prolonged
affective episodes are found quite consistently by earlier
research [20]. However, there were numerical differ-
ences between the groups in the expected direction on
these variables, so this difference could reach statistical
significance in a larger sample. Furthermore, the present
finding of no relationship between excessive substance
use and number of affective episodes is in line with pre-
vious research [49] although this is sparsely investigated.
Finally, the similar distribution of bipolar subtypes
across the groups in our study converges with some stu-
dies [20,83], but is contrary to those finding higher SUD
rates in bipolar I disorder compared to bipolar II disor-
der [1,6]. Our findings of no differences in BD illness
severity between patients with or without excessive sub-
stance use is in accordance with a recent study on BD I
disorder with or without SUD on several proxies for BD
severity [27].
The trend towards increased suicidality rates as well as
the lower GAF S scores found in the excessive substance
use group in the present study, could be signs of a
poorer general psychiatric outcome not linked to a
more severe BD. Increased suicidality is seen in a num-
ber of psychiatric disorders and has been found asso-
ciated with SUD alone [88], and with the combination
of SUD and a variety of psychiatric disorders [89-91].
Thus it appears reasonable to link the increased suicid-
ality more to the excessive substance use per se than to
a more severe BD course. The lower GAF S scores in
our excessive substance use group were not reflected in
increased symptoms as measured by the IDS and the
YMRS as could be expected, and may also be directly
related to the substance use itself or to the burden of
having two disorders. In summary, excessive substance
use does not appear to be related to more severe speci-
fic BD illness characteristics, but to a more severe gen-
eral psychiatric outcome in terms of worse global
clinical features unspecific to psychiatric diagnosis and
frequently seen in association with substance abuse
alone.
Our finding concerning psychosis is in accordance
with previous studies reporting a lack of association
between SUD and higher lifetime rates of psychosis in
BD [18]. This is not surprising given that these studies
did not specifically investigate the use of cannabis and
centrally stimulating agents known to induce psychotic
symptoms during intoxication [92,93] and increase the
risk of psychotic disorders [94,95]. The lack of associa-
tion between psychosis and excessive use of these psy-
chosis inducing substances found in the present study is
somewhat surprising, but could be related to a high psy-
chosis frequency in general in BD patients, thereby
reducing the relative effect of substance use.
The present study’s approach of adding patients with a
SUD-subthreshold excessive substance use to the SUD
group has additional value, in that we demonstrate that
SUD criteria are not necessarily the appropriate cut-off
when addressing and assessing harmful substance use in
BD. Our findings may also have important implications
for treatment of BD patients with excessive substance
use. Because of the increased functional impairment and
treatment non-compliance associated with excessive
substance use, substance use should be targeted in treat-
ment before the clinical signs of abuse or dependence
have developed. Our findings further demonstrate that
patients with a considerable amount and frequency of
substance use may not necessarily fulfill SUD diagnostic
criteria.
The inconsistency revealed in the literature regarding
differences in clinical and functional characteristics
between BD with and without SUD is somewhat unex-
pected, as several papers including reviews of the topic
generally state that there is consistent evidence that a
comorbid SUD is associated with more severe features.
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This is a relatively new field, thus citation and publica-
tion biases may be a problem. Studies also vary to a
great extent in operationalizations and methodology,
which may explain some of the discrepancies. Further-
more, studies setting out to answer questions about the
associations between comorbid SUD and outcome in
BD patients are few compared to studies that focus on
other issues and report relationships between comorbid
SUD and outcome as secondary findings. Also, since
only a few studies display effect sizes in addition to sig-
nificance levels, little is known about the strength of the
associations. Thus, there is a great need for more well-
designed and hypothesis-driven studies addressing this
question as well as future efforts to agree on
methodology.
The present study has some limitations. The sample in
the present study was too small to investigate current
use levels or non-alcoholic substance types separately.
Furthermore, since this is a cross-sectional study, no
conclusions of causality may be drawn regarding the
association between excessive substance use and the
functional level. Thus, whether these relationships are
due to negative effects from the excessive substance use,
or related socioeconomic factors, cannot be determined.
Also, the sample size is relatively small, with an
increased risk for type II errors. However, there are few
substantial numerical differences between the groups,
thus an increase in sample size would not lead to addi-
tional significant differences. This is a well characterized
catchment area study, covering both in- and outpatient
units including substance abuse clinics.
Conclusions
The current findings show that there is a significant
increase in illicit substance use in BD compared to gen-
eral population with an OR of 3. Patients with excessive
substance use have indications of impaired functioning
and some signs of a more severe general psychiatric out-
come, but not worse illness course characteristics or
current symptom levels. This has implications for cur-
rent treatment and should lead to more research into
the underlying psychopathological mechanisms.
Additional file 1: Additional file1provides an overview table of the
literature reported in the background section concerning the effect
of substance use disorders on BD. The table is organized in two parts;
Part I: “Reported effects of substance use disorders on measures of
functioning and general psychopathology”, and Part II: “Reported effects
of substance use disorders on measures of illness course and clinical
characteristics specific to bipolar disorder”. Some of the reviewed studies
appear in both Part I and Part II.
Click here for file
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S1.DOC ]
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